BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc.이(가) 2026년 9월 18일에 보고한 내용

기업이 직접 제출한 8-K에서 가져왔습니다.

실적 발표 컨퍼런스 콜

BlossomHill Therapeutics, Inc.의 실적 발표 콜 녹취록이 없습니다.

경영진의 발언

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter,”

발표 자료에서 그대로 인용했으며, 공시가 발언자를 실명으로 밝힌 경우에만 표시합니다.

주가는 어떻게 반응했나

실적 발표는 장 마감 후나 개장 전에 나오므로, 여기서 말하는 변동은 그다음 거래일입니다.

BlossomHill Therapeutics, Inc.은(는) 무엇을 하는 기업인가

BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR ™ inhibitor for the treatment of EGFR -mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories – classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions – while maintaining marked selectivity over wild-type EGFR. BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial spanning more than 40 sites in 10 countries. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov ( NCT06706076 ).

발표 자료 말미에 실린 기업 자신의 소개글입니다.